Evaluation of glycopeptide prescription and therapeutic drug monitoring at a University Hospital

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 3, 2010, Pages 177-184

  Roustit, Matthieu ^a   Franois, Patrice ^b   Sellier, Elodie ^b   Roch, Nathalie ^a   Vittoz, Jean Philippe ^b   Foroni, Luc ^a   Stahl, Jean Paul ^a   Pavese, Patricia ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG MISUSE; DRUG MONITORING; ENTEROBACTER; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PEDIATRIC WARD; PRACTICE GUIDELINE; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS; SURGICAL WARD; TREATMENT DURATION; TREATMENT INDICATION; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG MONITORING; DRUG UTILIZATION; FEMALE; FRANCE; GLYCOPEPTIDES; GUIDELINE ADHERENCE; HEALTH SERVICES RESEARCH; HOSPITALS, UNIVERSITY; HUMANS; MALE; PRESCRIPTIONS; PROSPECTIVE STUDIES;

EID: 76649141736     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365540903413614     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995;16: 105-113
2. Bolon MK, Arnold AD, Feldman HA, Rehkopf DH, Strong EF, Goldmann DA, et al. Evaluating vancomycin use at a pediatric hospital: new approaches and insights. Infect Control Hosp Epidemiol 2005;26:47-55.
3. Cieslak PR, Strausbaugh LJ, Fleming DW, Ling JM. Vancomycin in Oregon: who's using it and why. Infect Control Hosp Epidemiol 1999;20:557-560
4. Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996;17:356-359
5. Johnson SV, Hoey LL, Vance-Bryan K. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy 1995; 15:579-585
6. Levent T, Lambiotte F, Vasseur M, De Zorzi S, Gosteau L, Paradis P. Prospective assessment of glycopeptides prescriptions in a general hospital. Med Mal Infect 2005;35:411-416
7. Watanakunakorn C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767-769
8. Morgan AS, Brennan PJ, Fishman NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacother 1997;31:970-973
9. Anglim AM, Klym B, Byers KE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997;157:1132-1136
10. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006;12:92-95
11. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
12. Singer MV, Haft R, Barlam T, Aronson M, Shafer A, Sands KE. Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998;19:248-253
13. Helgason KO, Thomson AH, Ferguson C. A review of vancomycin therapeutic drug monitoring recommendations in Scotland. J Antimicrob Chemother 2008;61: 1398-1399
14. Sato M, Chida K, Suda T, Muramatsu H, Suzuki Y, Hashimoto H, et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother 2006;12:185-189
15. Thuong M, Shortgen F, Zazempa V, Girou E, Soussy CJ, Brun-Buisson C. Appropriate use of restricted antimicrobial agents in hospitals: the importance of empirical therapy and assisted re-evaluation. J Antimicrob Chemother 2000;46:501-508
16. Evans ME, Millheim ET, Rapp RP. Vancomycin use in a university medical center: effect of a vancomycin continuation form. Infect Control Hosp Epidemiol 1999;20: 417-420
17. Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 2001;47:246.
18. Nakayama H, Echizen H, Tanaka M, Sato M, Orii T. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther Drug Monit 2008;30: 103-107
19. Paladino JA, Sunderlin JL, Adelman MH, Singer ME, Schentag JJ. Observations on vancomycin use in U.S. hospitals. Am J Health Syst Pharm 2007;64:1633-1641
20. Bingen E, Mariani-Kurkdjian P, Nebbad B. Optimal vancomycin serum level in Staphylococcus aureus infections? Med Mal Infect 2006;36:439-442
21. Willemsen I, Groenhuijzen A, Bogaers D, Stuurman A, van Keulen P, Kluytmans J. Appropriateness of antimicrobial therapy measured by repeated prevalence surveys. Antimicrob Agents Chemother 2007;51:864-867
22. Lacombe K, Cariou S, Tilleul P, Offenstadt G, Meynard JL. Optimizing fluoroquinolone utilization in a public hospital: a prospective study of educational intervention. Eur J Clin Microbiol Infect Dis 2005;24:6-11.